Clinical trials
ARDS (Moderate or Severe) clinical trials
Below are recruiting ards (moderate or severe) clinical trials, each written for real people, not researchers. We’re tracking 1,471 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07039669RecruitingPhase 3
Study of 611 for moderate to severe COPD in adults
This trial tests a new medicine called 611 for people with moderate to severe COPD. It aims to see if adding 611 to your current treatments can help prevent flare-ups and improve symptoms.
Beijing, Beijing MunicipalityAges 40–85 - NCT07038720RecruitingPhase 1
Testing an experimental oral tablet for moderate to severe psoriasis
This early-phase study tests an experimental oral tablet (UA026) in people with moderate to severe plaque psoriasis. The purpose is to see how safe and effective the drug is, and how it works in the body.
Hangzhou, ZhejiangAges 18–55 - NCT07042126RecruitingPhase 3
Testing 611 for Teen Eczema (moderate to severe)
This trial tests a new injectable medicine (611) for teenagers with moderate to severe eczema that hasn't been helped enough by creams. It aims to see if the drug can safely reduce itching and skin symptoms.
Beijing, Beijing MunicipalityAges 12–17 - NCT07036133RecruitingPhase 1
Study of Pralatrexate in patients with advanced cancer and liver problems
This trial tests a drug called pralatrexate in people with advanced solid tumors or blood cancers, including those with different levels of liver function. The goal is to understand how the drug works in the body and how safe it is for patients with various degrees of liver impairment.
Cerritos, CaliforniaAges 18 years+ - NCT07037901RecruitingPhase 2
Testing IMG-007 for moderate-to-severe eczema
This study tests a new medicine called IMG-007 for adults with moderate-to-severe eczema (atopic dermatitis) that hasn't gotten better with standard creams. The goal is to see if it safely reduces itching and skin symptoms.
Lancaster, CaliforniaAges 18–74 - NCT07034664Recruiting
Ultrasound to predict Guselkumab response in Crohn's disease
This trial tests if a medication called Guselkumab can help people with moderate to severe Crohn's disease. It uses a special ultrasound to see how the bowel responds to treatment.
Changsha, HunanAges 18–80 - NCT07031713RecruitingPhase 1
Testing CT1192 cells for lupus that hasn't responded to treatment
This trial tests a new treatment called CT1192, which uses your own immune cells (T-cells) that are modified to target and calm overactive immune cells causing lupus. It is designed for people with moderate to severe lupus that hasn't improved with standard therapies like steroids, immunosuppressants, or biologics.
Wuhan, HubeiAges 18–60 - NCT07017686Recruiting
Reboot Study: Nerve stimulation for rheumatoid arthritis
This study tests a device that sends mild electrical pulses to the vagus nerve in the abdomen to treat rheumatoid arthritis. It is for people whose arthritis has not improved after trying multiple medications.
Fitzroy, VictoriaAges 18–75 - NCT07010835RecruitingPhase 1/Phase 2
Study of YK012 for moderate to severe lupus
This trial tests a new drug, YK012, for people with moderate to severe lupus. It aims to see if the drug can reduce disease activity and improve symptoms.
Beijing, Beijing MunicipalityAges 18–75 - NCT07011524RecruitingPhase 2
Study of CM512 injection for moderate-to-severe asthma
This trial tests a new injection, CM512, for people with moderate-to-severe asthma that is not well controlled with current inhalers. It aims to see if the treatment can reduce asthma attacks and improve symptom control.
Guangzhou, GuangdongAges 18–75 - NCT07007637Enrolling by invitationPhase 3
Long-Term Safety and Effectiveness of Sonelokimab for Hidradenitis Suppurativa
This study offers long-term treatment with an investigational biologic, sonelokimab, for people with moderate to severe hidradenitis suppurativa who finished an earlier sonelokimab study. The goal is to see if sonelokimab remains safe and effective over time.
Birmingham, AlabamaAges 12 years+ - NCT07008703RecruitingPhase 1/Phase 2
Study of sss40 for cancer bone pain
This trial tests a new injection called sss40 to treat moderate-to-severe pain caused by cancer that has spread to the bones. The goal is to see if it is safe and effective for people whose pain is not being controlled by current treatments.
Zhengzhou, HenanAges 18 years+ - NCT07012395RecruitingPhase 2
Long-acting antibodies for moderate to severe ulcerative colitis
This study tests new long-acting antibodies, given alone or in combination, for people with moderate to severe ulcerative colitis. The goal is to see if these treatments can help reduce inflammation and improve symptoms.
Canoga Park, CaliforniaAges 18–75 - NCT06994650RecruitingPhase 3
Study of HRS9531 for sleep apnea and obesity
This trial tests an injection called HRS9531 to see if it helps people with obstructive sleep apnea (OSA) and obesity who already use a CPAP or similar breathing device. It may help by reducing weight and improving breathing during sleep.
Beijing, Beijing MunicipalityAges 18–75 - NCT06995352Enrolling by invitationPhase 4
Better pain relief after ankle surgery
This trial compares two methods of pain management after ankle surgery: a one-time injection of long-lasting numbing medicine (liposomal bupivacaine) versus a continuous nerve block via a small tube (catheter) placed near the nerve. The goal is to find which approach provides better pain relief with fewer side effects.
La Jolla, CaliforniaAges 18 years+ - NCT06999941Enrolling by invitation
Study of deucravacitinib for psoriasis with eczema features
This trial tests an oral medication called deucravacitinib for people who have both psoriasis and eczema (or psoriasis that looks like eczema) on their skin. The goal is to see if it can help reduce the severity of their plaques and itch.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06988605Recruiting
Nemolizumab for teens and adults with moderate-to-severe eczema
This study looks at how well nemolizumab works in everyday practice for people with moderate-to-severe atopic dermatitis (eczema). It helps researchers understand the real-world benefits and safety of this treatment.
Birmingham, AlabamaAges 12 years+ - NCT06988618Recruiting
Real-world use of nemolizumab for adults with prurigo nodularis
This study looks at how well nemolizumab works in real-world settings for adults with moderate-to-severe prurigo nodularis, a skin condition that causes intense itching and bumps. If you are starting this medication as part of your normal care, you may be able to join.
Birmingham, AlabamaAges 18 years+ - NCT05440227RecruitingPhase 2
PG2 shots to reduce moderate to severe breast cancer fatigue
This Phase 2 trial tests whether PG2 injections can safely reduce moderate to severe fatigue in people receiving chemotherapy for locally advanced, recurrent, or metastatic breast cancer. If you qualify, you may be asked to complete questionnaires and follow study plans for about 8 weeks.
TaipeiAges 20 years+ - NCT06979336RecruitingPhase 2
New drug for moderate to severe UC
This study tests an experimental drug called RO7837195 for people with moderate to severe ulcerative colitis (UC) who haven't gotten enough help from other treatments. It aims to see if this new drug can reduce inflammation and improve symptoms.
Lancaster, CaliforniaAges 18 years+ - NCT06979453RecruitingPhase 3
A study of deucravacitinib for teens with plaque psoriasis
This trial tests an investigational oral medication called deucravacitinib for teenagers (adolescents) with moderate to severe plaque psoriasis. It aims to see if the drug is safe and works well.
Birmingham, AlabamaAges 12–17 - NCT06977581RecruitingPhase 2
Study of PF-07275315 for moderate-to-severe asthma
This study tests an investigational medicine called PF-07275315 for people with moderate-to-severe asthma that is not well controlled with current treatments. The goal is to see if it can reduce asthma attacks and improve breathing.
Mobile, AlabamaAges 18–75 - NCT06963177RecruitingPhase 2
Study of GenSci048 for endometriosis pain
This trial tests a new drug called GenSci048 to see if it can reduce moderate to severe pain caused by endometriosis. It might be an option if you have regular periods and are willing to switch to only the pain relievers allowed in the study.
Beijing, Beijing MunicipalityAges 18–49 - NCT06967857RecruitingPhase 2
Dexamfetamine for adults with ADHD and depression
This trial tests a study medication (dexamfetamine) for adults who have both ADHD and moderate to severe depression. It aims to see if the medication is safe and helps improve both conditions.
BerlinAges 18–65
Hear when a new ARDS (Moderate or Severe) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ards (moderate or severe)?
- Yes. Clin2 currently lists 1,471 recruiting ards (moderate or severe) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ards (moderate or severe) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ards (moderate or severe) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.